Pricing Log in Create free account

Burning Rock Biotech Limited Sponsored ADR (BNR) vs Myriad Genetics, Inc. (MYGN)

Burning Rock Biotech Limited Sponsored ADR and Myriad Genetics, Inc. are both Diagnostics & Research companies. Myriad Genetics, Inc. is the larger, with a market value of $416.1M against $137.1M — 3.0× the size. Burning Rock Biotech Limited Sponsored ADR grew revenue faster over the last twelve months: −0.14% against −3.16%. Burning Rock Biotech Limited Sponsored ADR has the higher net margin (−13.5% vs −14.0%) and the lower return on invested capital (−50.7% vs −19.9%). Across the 18 metrics below, Burning Rock Biotech Limited Sponsored ADR leads on 10 and Myriad Genetics, Inc. on 8.

Valuation

Metric BNR MYGN Diagnostics & Research median
P/E n/m n/m 35.56
P/S 18.73 0.47 4.37
P/B 18.81 1.24 3.06
Price to free cash flow n/m n/m 35.76
EV/EBITDA n/m n/m 24.35
EV/Sales 17.89 0.55 5.51
Earnings yield (4.09%) (29.90%) (1.89%)
Free cash flow yield (1.06%) (3.76%) (0.15%)

Profitability

Metric BNR MYGN Diagnostics & Research median
Gross margin 74.50% 68.83% 50.89%
Operating margin (12.95%) (12.22%) (8.57%)
Net margin (13.51%) (13.96%) (6.37%)
Free cash flow margin (3.00%) (1.76%) 0.00%
Return on equity (13.08%) (32.54%) (2.92%)
Return on assets (8.81%) (17.11%) (6.71%)
Return on invested capital (50.66%) (19.92%) 0.00%

Growth

Metric BNR MYGN Diagnostics & Research median
Revenue growth (TTM) (0.14%) (3.16%) 7.69%
EPS growth (last fiscal year) 84.16% (180.14%) 25.92%
Revenue growth, 5-year CAGR 3.21% 3.61% 7.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric BNR MYGN Diagnostics & Research median
Debt to equity 0.00 0.40 0.11
Current ratio 3.05 2.21 2.02
Net debt to EBITDA 14.48 2.11 0.70

Dividend

Metric BNR MYGN Diagnostics & Research median
Dividend yield — — 0.66%
Payout ratio — — 0.20

Size

Metric BNR MYGN Diagnostics & Research median
Market cap 137.12m 416.08m 2.16b

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack